Skip to main content
SpringerLink
Log in

The Use of Vitamin K in Patients on Anticoagulant Therapy

A Practical Guide

  • Therapy In Practice
  • Published:
American Journal of Cardiovascular Drugs Aims and scope Submit manuscript

Abstract

Anticoagulation with antivitamin K (AVK) is very effective for primary and secondary prevention of thromboembolic events. However, questions persist about the risks and management of over-anticoagulation. For reversal of excessive anticoagulation by warfarin, AVK withdrawal, oral or parenteral vitamin K administration, prothrombin complex or fresh frozen plasma may be used, depending on the excess of anticoagulation, the existence and site of active bleeding, patient characteristics and the indication for AVK. In over-anticoagulated patients, vitamin K aims at rapid lowering of the international normalized ratio (INR) into a safe range to reduce the risk of major bleeding and therefore improving patient outcome without exposing the patient to the risk of thromboembolism due to overcorrection, resistance to AVK, or an allergic reaction to the medication.

The risk of bleeding increases dramatically when the INR exceeds 4.0–6.0, although the absolute risk of bleeding remains fairly low, <5.5 per 1000 per day. Patient characteristics, including advanced age, treated hypertension, history of stroke, and concomitant use of various drugs, affect the risk of bleeding. The absolute risk of thromboembolism associated with overcorrection appears to be in the same range as the risk of bleeding due to over-anticoagulation. The use of vitamin K in patients with warfarin over-anticoagulation lowers excessively elevated INR faster than withholding warfarin alone; however, it has not been clearly demonstrated that vitamin K treatment does, in fact, lower the risk of major hemorrhage.

As vitamin K administration via the intravenous route may be complicated by anaphylactoid reactions, and via the subcutaneous route by cutaneous reactions, oral administration is preferred. A dose of 1–2.5mg of oral phytomenadione (vitamin K1), reduces the range of INR from 5.0–9.0 to 2.0–5.0 within 24–48 hours, and for an INR >10.0, a dose of 5mg may be more appropriate. Overcorrection of the INR or resistance to warfarin is unlikely if the above doses of vitamin K are used. Vitamin K is less effective for over-anticoagulation after treatment with acenocoumarol or phenprocoumon than after treatment with warfarin.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III
Table IV
Table V
Fig. 1

Similar content being viewed by others

References

  1. Gilman GA, Rall TW, Nies AS, Taylor P, editors. Goodman and Gilman’s the pharmacological basis of therapeutics, 88th edition. New York: Pergamon Press, 1990

    Google Scholar 

  2. Keller C, Matzdorff AC, Kemkes-Matthes B. Pharmacology of warfarin and clinical implications. Semin Thromb Hemost 1999; 25(1): 13–6

    CAS  PubMed  Google Scholar 

  3. Stroke Prevention in Atrial Fibrillation Investigators. Bleeding during antithrombotic therapy in patients with atrial fibrillation. Arch Intern Med 1996; 156(4): 409–16

    Google Scholar 

  4. Cannegieter SC, Rosendaal FR, Wintzen AR, et al. Optimal oral anticoagulant therapy in patients with mechanical heart valves. N Engl J Med 1995; 333(1): 11–7

    CAS  PubMed  Google Scholar 

  5. Ansell J, Hirsh J, Dalen J. Managing oral anticoagulant therapy. Chest 2001; 119(1 Suppl.): 22S–38S

    CAS  PubMed  Google Scholar 

  6. Nitu IC, Perry DJ, Lee CA. Clinical experience with the use of clotting factor concentrates in oral anticoagulation reversal. Clin Lab Haematol 1998; 20(6): 363–7

    CAS  PubMed  Google Scholar 

  7. Cartmill M, Dolan G, Byrne JL, et al. Prothrombin complex concentrate for oral anticoagulant reversal in neurosurgical emergencies. Br J Neurosurg 2000; 14(5): 458–61

    CAS  PubMed  Google Scholar 

  8. Makris M, Greaves M, Phillips WS, et al. Emergency oral anticoagulant reversal: the relative efficacy of infusions of fresh frozen plasma and clotting factor concentrate on correction of the coagulopathy. Thromb Haemost 1997; 77(3): 477–80

    CAS  PubMed  Google Scholar 

  9. Baglin T. Management of warfarin (coumarin) overdose. Blood Rev 1998; 12(2): 91–8

    CAS  PubMed  Google Scholar 

  10. Wilson SE, Douketis JD, Crowther MA. Treatment of warfarin-associated coagulopathy: a physician survey. Chest 2001; 120(6): 1972–6

    CAS  PubMed  Google Scholar 

  11. Hirsh J. Reversal of the anticoagulant effects of warfarin by vitamin K1. Chest 1998; 114(6): 1505–8

    CAS  PubMed  Google Scholar 

  12. Sweeney KG, Gray DP, Evans P, et al. Anticoagulation therapy: bleeding and thromboembolic complications. Lancet 1996; 348(9039): 1456–7

    CAS  PubMed  Google Scholar 

  13. Schenk JF, Morsdorf S, Pindur G, et al. Analysis and occurrence of adverse events with oral anticoagulant therapy. Semin Thromb Hemost 1999; 25(1): 65–71

    CAS  PubMed  Google Scholar 

  14. Levine MN, Raskob G, Landefeld S, et al. Hemorrhagic complications of anticoagulant treatment. Chest 2001; 119(1 Suppl.): 108S–21S

    CAS  PubMed  Google Scholar 

  15. Gage BF, Cardinalli AB, Albers GW, et al. Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillation. JAMA 1995; 274(23): 1839–45

    CAS  PubMed  Google Scholar 

  16. Palareti G, Leali N, Coccheri S, et al. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy. Lancet 1996; 348(9025): 423–8

    CAS  PubMed  Google Scholar 

  17. Glover JJ, Morrill GB. Conservative treatment of over-anticoagulated patients. Chest 1995; 108(4): 987–90

    CAS  PubMed  Google Scholar 

  18. Hylek EM, Chang YC, Skates SJ, et al. Prospective study of the outcomes of ambulatory patients with excessive warfarin anticoagulation. Arch Intern Med 2000; 160(11): 1612–7

    CAS  PubMed  Google Scholar 

  19. van der Meer FJ, Rosendaal FR, Vandenbroucke JP, et al. Bleeding complications in oral anticoagulant therapy: an analysis of risk factors. Arch Intern Med 1993; 153(13): 1557–62

    PubMed  Google Scholar 

  20. Casais P, Luceros AS, Meschengieser S, et al. Bleeding risk factors in chronic oral anticoagulation with acenocoumarol. Am J Hematol 2000; 63(4): 192–6

    CAS  PubMed  Google Scholar 

  21. Hart RG, Boop BS, Anderson DC. Oral anticoagulants and intracranial hemorrhage: facts and hypotheses. Stroke 1995; 26(8): 1471–7

    CAS  PubMed  Google Scholar 

  22. Ogg MS, Brennan P, Meade T, et al. CYP2C9*3 allelic variant and bleeding complications [letter]. Lancet 1999; 354(9184): 1124

    CAS  PubMed  Google Scholar 

  23. Beyth RJ, Quinn LM, Landefeld CS. Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am J Med 1998; 105(2): 91–9

    CAS  PubMed  Google Scholar 

  24. Landefeld CS, Beyth RJ. Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention. Am J Med 1993; 95(3): 315–28

    CAS  PubMed  Google Scholar 

  25. Fihn SD, McDonell M, Martin D, et al. Risk factors for complications of chronic anticoagulation: a multicenter study. Warfarin Optimized Outpatient Follow-up Study Group. Ann Intern Med 1993; 118(7): 511–20

    CAS  PubMed  Google Scholar 

  26. McMahan DA, Smith DM, Carey MA, et al. Risk of major hemorrhage for outpatients treated with warfarin. J Gen Intern Med 1998; 13(5): 311–6

    CAS  PubMed  PubMed Central  Google Scholar 

  27. Hylek EM, Singer DE. Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med 1994; 120(11): 897–902

    CAS  PubMed  Google Scholar 

  28. Brigden ML, Kay C, Le A, et al. Audit of the frequency and clinical response to excessive oral anticoagulation in an out-patient population. Am J Hematol 1998; 59(1): 22–7

    CAS  PubMed  Google Scholar 

  29. Wehinger C, Stollberger C, Langer T, et al. Evaluation of risk factors for stroke/ embolism and of complications due to anticoagulant therapy in atrial fibrillation. Stroke 2001; 32(10): 2246–52

    CAS  PubMed  Google Scholar 

  30. Petitti DB, Strom BL, Melmon KL. Prothrombin time ratio and other factors associated with bleeding in patients treated with warfarin. J Clin Epidemiol 1989; 42(8): 759–64

    CAS  PubMed  Google Scholar 

  31. Panneerselvam S, Baglin C, Lefort W, et al. Analysis of risk factors for overanticoagulation in patients receiving long-term warfarin. Br J Haematol 1998; 103(2): 422–4

    CAS  PubMed  Google Scholar 

  32. White RH, McKittrick T, Takakuwa J, et al. Management and prognosis of life-threatening bleeding during warfarin therapy. National Consortium of Anticoagulation Clinics. Arch Intern Med 1996; 156(11): 1197–201

    CAS  PubMed  Google Scholar 

  33. Kuijer PM, Hutten BA, Prins MH, et al. Prediction of the risk of bleeding during anticoagulant treatment for venous thromboembolism. Arch Intern Med 1999; 159(5): 457–60

    CAS  PubMed  Google Scholar 

  34. Hylek EM, Heiman H, Skates SJ, et al. Acetaminophen and other risk factors for excessive warfarin anticoagulation. JAMA 1998; 279(9): 657–62

    CAS  PubMed  Google Scholar 

  35. Aithal GP, Day CP, Kesteven PJ, et al. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 1999; 353(9154): 717–9

    CAS  PubMed  Google Scholar 

  36. Hylek EM, Regan S, Go AS, et al. Clinical predictors of prolonged delay in return of the international normalized ratio to within the therapeutic range after excessive anticoagulation with warfarin. Ann Intern Med 2001; 135(6): 393–400

    CAS  PubMed  Google Scholar 

  37. White RH, McKittrick T, Hutchinson R, et al. Temporary discontinuation of warfarin therapy: changes in the international normalized ratio. Ann Intern Med 1995; 122(1): 40–2

    CAS  PubMed  Google Scholar 

  38. Gadisseur AP, van der Meer FJ, Adriaansen HJ, et al. Therapeutic quality control of oral anticoagulant therapy comparing the short-acting acenocoumarol and the long-acting phenprocoumon. Br J Haematol 2002; 117(4): 940–6

    CAS  PubMed  Google Scholar 

  39. Watson HG, Baglin T, Laidlaw SL, et al. A comparison of the efficacy and rate of response to oral and intravenous vitamin K in reversal of over-anticoagulation with warfarin. Br J Haematol 2001; 115(1): 145–9

    CAS  PubMed  Google Scholar 

  40. Raj G, Kumar R, McKinney WP. Time course of reversal of anticoagulant effect of warfarin by intravenous and subcutaneous phytonadione. Arch Intern Med 1999; 159(22): 2721–4

    CAS  PubMed  Google Scholar 

  41. Lousberg TR, Witt DM, Beall DG, et al. Evaluation of excessive anticoagulation in a group model health maintenance organization. Arch Intern Med 1998; 158(5): 528–34

    CAS  PubMed  Google Scholar 

  42. Watson HG, Baglin TP, Makris M. The use of oral vitamin K for reversal of overwarfarinization [letter]. Br J Haematol 2002; 116(1): 237

    PubMed  Google Scholar 

  43. Fiore LD, Scola MA, Cantillon CE, et al. Anaphylactoid reactions to vitamin K. J Thromb Thrombolysis 2001; 11(2): 175–83

    CAS  PubMed  Google Scholar 

  44. Penning-van Beest FJ, Rosendaal FR, Grobbee DE, et al. Course of the International Normalized Ratio in response to oral vitamin K1 in patients overanticoagulated with phenprocoumon. Br J Haematol 1999; 104(2): 241–5

    Google Scholar 

  45. Fondevila CG, Grosso SH, Santarelli MT, et al. Reversal of excessive oral anticoagulation with a low oral dose of vitamin K1 compared with acenocoumarine discontinuation: a prospective, randomized, open study. Blood Coagul Fibrinolysis 2001; 12(1): 9–16

    CAS  PubMed  Google Scholar 

  46. Pengo V, Banzato A, Garelli E, et al. Reversal of excessive effect of regular anticoagulation: low oral dose of phytonadione (vitamin K1) compared with warfarin discontinuation. Blood Coagul Fibrinolysis 1993; 4(5): 739–41

    CAS  PubMed  Google Scholar 

  47. Shetty HG, Backhouse G, Bentley DP, et al. Effective reversal of warfarin-induced excessive anticoagulation with low dose vitamin K1. Thromb Haemost 1992; 67(1): 13–5

    CAS  PubMed  Google Scholar 

  48. Brophy MT, Fiore LD, Deykin D. Low-dose vitamin K therapy in excessively anticoagulated patients: a dose-finding study. J Thromb Thrombolysis 1997; 4(2): 289–92

    CAS  PubMed  Google Scholar 

  49. Hung A, Singh S, Tait RC. A prospective randomized study to determine the optimal dose of intravenous vitamin K in reversal of over-warfarinization. Br J Haematol 2000; 109(3): 537–9

    CAS  PubMed  Google Scholar 

  50. Fetrow CW, Overlock T, Leff L. Antagonism of warfarin-induced hypoprothrombinemia with use of low-dose subcutaneous vitamin K1. J Clin Pharmacol 1997; 37(8): 751–7

    CAS  PubMed  Google Scholar 

  51. Byrd DC, Stephens MA, Hamann GL, et al. Subcutaneous phytonadione for reversal of warfarin-induced elevation of the International Normalized Ratio. Am J Health Syst Pharm 1999; 56(22): 2312–5

    CAS  PubMed  Google Scholar 

  52. Weibert RT, Le DT, Kayser SR, et al. Correction of excessive anticoagulation with low-dose oral vitamin K1. Ann Intern Med 1997; 126(12): 959–62

    CAS  PubMed  Google Scholar 

  53. Crowther MA, Donovan D, Harrison L, et al. Low-dose oral vitamin K reliably reverses over-anticoagulation due to warfarin. Thromb Haemost 1998; 79(6): 1116–8

    CAS  PubMed  Google Scholar 

  54. Wentzien TH, O’Reilly RA, Kearns PJ. Prospective evaluation of anticoagulant reversal with oral vitamin K1 while continuing warfarin therapy unchanged. Chest 1998; 114(6): 1546–50

    CAS  PubMed  Google Scholar 

  55. Pendry K, Bhavnani M, Shwe K. The use of oral vitamin K for reversal of over-warfarinization. Br J Haematol 2001; 113(3): 839–40

    CAS  PubMed  Google Scholar 

  56. Patel RJ, Witt DM, Saseen JJ, et al. Randomized, placebo-controlled trial of oral phytonadione for excessive anticoagulation. Pharmacotherapy 2000; 20(10): 1159–66

    CAS  PubMed  Google Scholar 

  57. Crowther MA, Julian J, McCarty D. Treatment of warfarin-associated coagulopathy with oral vitamin K: a randomised controlled trial. Lancet 2000; 356(9241): 1551–3

    CAS  PubMed  Google Scholar 

  58. Kearon C, Hirsh J. Management of anticoagulation before and after elective surgery. N Engl J Med 1997; 336(21): 1506–11

    CAS  PubMed  Google Scholar 

  59. Palareti G, Legnani C. Warfarin withdrawal: pharmacokinetic-pharmacodynamic considerations. Clin Pharmacokinet 1996; 30(4): 300–13

    CAS  PubMed  Google Scholar 

  60. Palareti G, Legnani C, Guazzaloca G, et al. Activation of blood coagulation after abrupt or stepwise withdrawal of oral anticoagulants: a prospective study. Thromb Haemost 1994; 72(2): 222–6

    CAS  PubMed  Google Scholar 

  61. Genewein U, Haeberli A, Straub PW, et al. Rebound after cessation of oral anticoagulant therapy: the biochemical evidence. Br J Haematol 1996; 92(2): 479–85

    CAS  PubMed  Google Scholar 

  62. de la Rubia J, Grau E, Montserrat I, et al. Anaphylactic shock and vitamin K1 [letter]. Ann Intern Med 1989; 110(11): 943

    PubMed  Google Scholar 

  63. Chung JY, Ramos-Caro FA, Beers B, et al. Hypersensitivity reactions to parenteral vitamin K. Cutis 1999; 63(1): 33–4

    CAS  PubMed  Google Scholar 

  64. Gettler SL, Fung MA. Off-center fold: indurated plaques on the arms of a 52-year-old man. Diagnosis: cutaneous reaction to phytonadione injection. Arch Dermatol 2001; 137(7): 957–62

    CAS  PubMed  Google Scholar 

  65. White RH, Minton SM, Andya MD, et al. Temporary reversal of anticoagulation using oral vitamin K. J Thromb Thrombolysis 2000; 10(2): 149–53

    CAS  PubMed  Google Scholar 

  66. Bonow RO, Carabello B, de Leon Jr AC, et al. Guidelines for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients with Valvular Heart Disease). Circulation 1998; 98(18): 1949–84

    CAS  PubMed  Google Scholar 

  67. Gallus AS, Baker RI, Chong BH, et al. Consensus guidelines for warfarin therapy: recommendations from the Australasian Society of Thrombosis and Haemostasis. Med J Aust 2000; 172(12): 600–5

    CAS  PubMed  Google Scholar 

  68. Haemotases and thombosis task force, British Society for Haematology. Guidelines on oral anticoagulation: third edition. Br J Haematol 1998; 101(2): 374–87

    Google Scholar 

Download references

Acknowledgements

We are grateful to Shéhérazade Ouaret, MD, of the French Health Security Agency, AFSSAPS, for her help in collecting national pharmacovigilance information. No sources of funding were used to assist in the preparation of this manuscript. The authors have no conflicts of interest that are directly relevant to the content of this manuscript.

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Ambroise Paré Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France

    Thomas Hanslik & Jacques Prinseau

  2. Université de Versailles, Saint-Quentin-en-Yvelines, France

    Thomas Hanslik & Jacques Prinseau

Authors
  1. Thomas Hanslik
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jacques Prinseau
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Thomas Hanslik.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hanslik, T., Prinseau, J. The Use of Vitamin K in Patients on Anticoagulant Therapy. Am J Cardiovasc Drugs 4, 43–55 (2004). https://doi.org/10.2165/00129784-200404010-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00129784-200404010-00005

Keywords

Search

Navigation